Shots: The companies expand their existing collaboration to develop & commercialize RNAi therapies targeting SARS-CoV-2 utilizing Alnylam’s advances in lung delivery of novel conjugates of siRNA along with Vir’s infectious […]readmore
Tags : 2017
Shots: Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option In 2017, Novartis signed an option agreement with Akcea for two antisense […]readmore